US · BNBX
BNB Plus Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Stony Brook, NY 11790
- Website
- bnbx.io
Price · as of 2025-09-30
$0.50
Market cap 910.41K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | |||||
| 2025 | $3.00 |
AI valuation
Our deep-learning model estimates BNB Plus Corp.'s (BNBX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.50
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BNBX | BNB Plus Corp. | $0.50 | 910.41K | — | — | — | — | -0.10 | 0.67 | 0.73 | -0.01 | — | 0.67 | 39.26% | -750.92% | -709.46% | — | — | — | 0.08 | — | 0.91 | 0.77 | 0.09 | — | — | — | -826.25% | -5.08 | — | 0.00% | 0.00% | 0.00% | 0.00 | -0.01 | 0.04 | -130.76 |
| BGMS | Bio Green Med Solution, I… | $0.98 | 1.89M | +2,199,316% | +3,759,305% | — | +3,987,072% | -0.07 | -0.38 | 19.24 | 0.19 | — | -0.38 | 100.00% | -27916.28% | -26074.42% | 1431.01% | 278.96% | -173.84% | 0.00 | — | 0.59 | 0.54 | 0.26 | -9219.00% | -8976.00% | -5043.00% | -965.78% | -1.27 | 198.63% | 0.00% | 0.00% | 0.00% | 0.19 | 0.29 | -53.71 | -160.64 |
| BNGO | Bionano Genomics, Inc. | $1.15 | 3.78M | +6,408% | +42% | — | +30,750% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| ISPC | iSpecimen Inc. | $0.25 | 1.39M | +15,728% | +124% | — | — | -0.08 | 0.30 | 0.11 | 0.04 | — | -0.50 | 42.93% | -136.99% | -134.51% | -191.51% | -381.28% | -99.31% | 0.09 | -57.84 | 0.62 | 0.58 | 0.12 | -2839.00% | -642.00% | -2115.00% | -830.12% | -1.43 | -249.24% | 0.00% | 0.00% | 0.00% | 0.04 | 0.07 | -0.06 | -14.44 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| NAOV | NanoVibronix, Inc. | $2.26 | 1.8M | +62,596% | +597% | — | — | -2.87 | 16.95 | 4.15 | -2.71 | — | 16.95 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -3524.00% | 1205.00% | -3009.00% | -23.70% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -2.79 | -3.97 | 3.91 | -27.16 |
| NDRA | ENDRA Life Sciences Inc. | $4.15 | 3.12M | — | — | — | — | -0.34 | 1.54 | — | -0.12 | -0.46 | 1.54 | 0.00% | — | — | -280.02% | -690.14% | -205.38% | 0.23 | — | 5.67 | 5.34 | 0.25 | 7402.00% | — | -2260.00% | -188.25% | -12.23 | -473.18% | 0.13% | 0.00% | 5.35% | -0.12 | -0.17 | — | -38.53 |
| RDHL | RedHill Biopharma Ltd. | $0.97 | 3.23M | +40,100% | +30% | — | — | -0.94 | -1.66 | 0.97 | -0.46 | — | -0.76 | 60.31% | -181.69% | -102.80% | 632.60% | 242.32% | -40.24% | -0.08 | -265.69 | 0.54 | 0.37 | 0.56 | -11522.00% | 2317.00% | -7383.00% | -120.72% | -0.42 | 155.51% | 0.00% | 0.00% | 0.00% | -0.24 | -0.37 | 0.44 | -34.89 |
| VERO | Venus Concept Inc. | $0.31 | 576.33K | +37,326% | +290% | — | +132,842% | -0.05 | 0.91 | 0.03 | -1.14 | -0.01 | -0.83 | 68.34% | -41.93% | -72.49% | 806.37% | -52.93% | -58.05% | 18.16 | -3.55 | 1.60 | 0.78 | -1.08 | 86901.00% | -1509.00% | -1376.00% | -520.15% | -0.37 | -22.07% | 0.00% | 0.00% | 1652.41% | -1.50 | -3.66 | 0.63 | -6.37 |
About BNB Plus Corp.
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
- CEO
- Clay D. Shorrock
- Employees
- 46
- Beta
- 0.57
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.50) − 1 = — (DCF, example).